Hypoxia Inducible Factors’ Signaling in Pediatric High-Grade Gliomas: Role, Modelization and Innovative Targeted Approaches
暂无分享,去创建一个
B. Lhermitte | M. Dontenwill | N. Entz-Werlé | Quentin Fuchs | Marina Pierrevelcin | Melissa Messe | Benoit Lhermitte | Anne-Florence Blandin | Christophe Papin | Andres Coca | Monique Dontenwill | Natacha Entz-Werlé | C. Papin | Q. Fuchs | Marina Pierrevelcin | M. Messe | A. Blandin | A. Coca | Christophe Papin | M. Messé | Quentin Fuchs
[1] J. Cervós-Navarro,et al. Selective vulnerability in brain hypoxia. , 1991, Critical reviews in neurobiology.
[2] J Meixensberger,et al. Clinical experience with 118 brain tissue oxygen partial pressure catheter probes. , 1998, Neurosurgery.
[3] Daniel J Brat,et al. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. , 2005, Neuro-oncology.
[4] Daniel J Brat,et al. 'Pseudopalisading' Necrosis in Glioblastoma: A Familiar Morphologic Feature That Links Vascular Pathology, Hypoxia, and Angiogenesis , 2006, Journal of neuropathology and experimental neurology.
[5] P. Ratcliffe. HIF-1 and HIF-2: working alone or together in hypoxia? , 2007, The Journal of clinical investigation.
[6] J. Pouysségur,et al. Oxygen, a source of life and stress , 2007, FEBS letters.
[7] Hui Wang,et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. , 2009, Cancer cell.
[8] L. Denaro,et al. Hypoxia and HIF1α Repress the Differentiative Effects of BMPs in High‐Grade Glioma , 2009, Stem cells.
[9] J. Engh,et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α , 2009, Oncogene.
[10] R. Deberardinis,et al. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. , 2009, Cancer research.
[11] R. Scienza,et al. Intratumoral Hypoxic Gradient Drives Stem Cells Distribution and MGMT Expression in Glioblastoma , 2010, Stem cells.
[12] A. Józkowicz,et al. HIF-1 and HIF-2 transcription factors — Similar but not identical , 2010, Molecules and cells.
[13] Alfredo Quiñones-Hinojosa,et al. Oxygen in stem cell biology: a critical component of the stem cell niche. , 2010, Cell stem cell.
[14] A. Ashworth,et al. A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas , 2010, Clinical Cancer Research.
[15] Peter Canoll,et al. Magnetic Resonance Imaging Characteristics of Glioblastoma Multiforme: Implications for Understanding Glioma Ontogeny , 2010, Neurosurgery.
[16] T. MacDonald,et al. Treatment of high-grade glioma in children and adolescents. , 2011, Neuro-oncology.
[17] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[18] David T. W. Jones,et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.
[19] N. Potter,et al. A Prominin-1-Rich Pediatric Glioblastoma: Biologic Behavior Is Determined by Oxygen Tension-Modulated CD133 Expression but Not Accompanied by Underlying Molecular Profiles. , 2012, Translational oncology.
[20] Chris Jones,et al. Lactate and Choline Metabolites Detected In Vitro by Nuclear Magnetic Resonance Spectroscopy Are Potential Metabolic Biomarkers for PI3K Inhibition in Pediatric Glioblastoma , 2014, PloS one.
[21] Kuniaki Saito,et al. H3F3A K27M mutations in thalamic gliomas from young adult patients. , 2014, Neuro-oncology.
[22] E. Kleinerman,et al. Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. , 2014, Anticancer research.
[23] Stephen Yip,et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma , 2014, Nature Genetics.
[24] Michael L Mumert,et al. Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome. , 2014, Neuro-oncology.
[25] Abdel Kareem Azab,et al. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy , 2015, Hypoxia.
[26] Jill S Barnholtz-Sloan,et al. Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. , 2015, Neuro-oncology.
[27] R. Wenger,et al. Frequently asked questions in hypoxia research , 2015, Hypoxia.
[28] P. Varlet,et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes , 2015, Acta Neuropathologica.
[29] S. Påhlman,et al. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. , 2016, Pharmacology & therapeutics.
[30] G. Semenza,et al. Dynamic regulation of stem cell specification and maintenance by hypoxia-inducible factors. , 2016, Molecular aspects of medicine.
[31] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[32] F. Ducray,et al. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort , 2016, Acta Neuropathologica.
[33] G. Semenza,et al. Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. , 2016, Trends in cancer.
[34] P. Ratcliffe,et al. New horizons in hypoxia signaling pathways , 2017, Experimental cell research.
[35] E. Letouzé,et al. Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1a axis inhibition. , 2017, Oncotarget.
[36] M. D. de Miguel,et al. Metabolic Reprogramming, Autophagy, and Reactive Oxygen Species Are Necessary for Primordial Germ Cell Reprogramming into Pluripotency , 2017, Oxidative medicine and cellular longevity.
[37] David R. Jones,et al. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme. , 2017, Journal of neurosurgery.
[38] M. Monje,et al. Neural Precursor-Derived Pleiotrophin Mediates Subventricular Zone Invasion by Glioma , 2017, Cell.
[39] S. Vajapeyam,et al. Correlation of 18F-FDG PET and MRI Apparent Diffusion Coefficient Histogram Metrics with Survival in Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium , 2017, The Journal of Nuclear Medicine.
[40] Kun Mu,et al. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma , 2017, Cancer cell.
[41] Ji-Yong Um,et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations , 2018, Nature.
[42] David T. W. Jones,et al. Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial , 2018, Cancer cell.
[43] M. Monje,et al. International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma , 2018, Journal of Neuro-Oncology.
[44] P. Morgan,et al. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] I. Sardi,et al. Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier , 2018, International journal of molecular sciences.
[46] David T. W. Jones,et al. Transcriptomic and epigenetic profiling of ‘diffuse midline gliomas, H3 K27M-mutant’ discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location , 2018, Acta Neuropathologica Communications.
[47] G. Semenza,et al. Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors. , 2018, Biochimica et biophysica acta. Reviews on cancer.
[48] J. Fangusaro,et al. REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature , 2017, Oncotarget.
[49] N. Forsyth,et al. Reactive Oxygen Species Formation in the Brain at Different Oxygen Levels: The Role of Hypoxia Inducible Factors , 2018, Front. Cell Dev. Biol..
[50] M. D. Del Bigio,et al. Characterization of the ventricular-subventricular stem cell niche during human brain development , 2018, Development.
[51] S. Khatua,et al. Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Tracy T Batchelor,et al. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq , 2018, Science.
[53] S. Pomeroy,et al. Brain cancer genomics and epigenomics. , 2018, Handbook of clinical neurology.
[54] K. Warren. Beyond the Blood:Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma , 2018, Front. Oncol..
[55] Michael C. Rusch,et al. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo , 2019, Acta Neuropathologica.
[56] D. Steindler,et al. 3D extracellular matrix microenvironment in bioengineered tissue models of primary pediatric and adult brain tumors , 2019, Nature Communications.
[57] D. Felsher,et al. MYC regulates the HIF-2α stemness pathway via Nanog and Sox2 to maintain self-renewal in cancer stem cells versus non-stem cancer cells. , 2019, Cancer research.
[58] M. Jolly,et al. Acute vs. Chronic vs. Cyclic Hypoxia: Their Differential Dynamics, Molecular Mechanisms, and Effects on Tumor Progression , 2019, Biomolecules.
[59] Beisi Xu,et al. Correction to: H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo , 2019, Acta Neuropathologica.
[60] J. Grill,et al. Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand? , 2019, Journal of Neuro-Oncology.
[61] B. Lhermitte,et al. Hypoxic Environment and Paired Hierarchical 3D and 2D Models of Pediatric H3.3-Mutated Gliomas Recreate the Patient Tumor Complexity , 2019, Cancers.
[62] Shawn M. Gillespie,et al. Electrical and synaptic integration of glioma into neural circuits , 2019, Nature.
[63] Richard A. Moore,et al. Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. , 2019, Cancer research.
[64] A. Panigrahy,et al. Quantifying radiation therapy response using apparent diffusion coefficient (ADC) parametric mapping of pediatric diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium , 2019, Journal of Neuro-Oncology.
[65] Jeff F Dunn,et al. Partial pressure of oxygen in the human body: a general review. , 2019, American journal of blood research.
[66] Qiuge Qiao,et al. Chronic mild hypoxia promotes hippocampal neurogenesis involving Notch1 signaling in epileptic rats , 2019, Brain Research.
[67] Matthew D. Dun,et al. Signal Transduction in Diffuse Intrinsic Pontine Glioma , 2019, Proteomics.
[68] Pieter Wesseling,et al. cIMPACT‐NOW: a practical summary of diagnostic points from Round 1 updates , 2019, Brain pathology.
[69] Rebecca A. Ihrie,et al. Location-dependent maintenance of intrinsic susceptibility to mTORC1-driven tumorigenesis , 2019, Life Science Alliance.
[70] Atique U. Ahmed,et al. Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma , 2019, The Journal of Neuroscience.
[71] C. Hawkins,et al. Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas , 2019, Neuro-oncology.
[72] O. Gevaert,et al. Whole slide images reflect DNA methylation patterns of human tumors , 2020, npj Genomic Medicine.
[73] Andreas Holzinger,et al. Open Data for Differential Network Analysis in Glioma , 2020, International journal of molecular sciences.